The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
The new guidelines will facilitate the design and development of clinical trials to test new therapies to minimize the burden of neurologic disability produced by neurosarcoidosis.
Approximately 5.5 million Americans have Alzheimer disease or dementia.
Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.
Decline in episodic memory scores seen with older age slower after vs before cataract surgery.
Findings among individuals with a genetic mutation known to cause Alzheimer's.
The new guidelines place a substantial emphasis on the importance of introducing high-quality rehabilitation early in these patients.
Benefits seen were greater than for social interaction alone in older black population.
Sensitivity, specificity, accuracy values of 79, 84, and 81% for detecting PD from controls.
As the neurodegenerative processes of Alzheimer disease and Parkinson disease are different, early cognitive impairment also present differently in these diseases.
Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer's disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.
Increased prevalence of deficits in visual function vs typically developing school-age children.
Thinning of the retinal nerve fiber layer has been linked to worsening cognitive function and may be valuable in identifying individuals who may be at risk for cognitive decline.
Hormone therapy in postmenopausal women with mild cognitive impairment was examined.
Researchers assessed whether current metabolic parameters are inversely associated with cognitive functioning.
Lower BCAA levels may be associated with an increased risk of incident dementia.
Psychological impairment seen particularly in those with chronic health conditions
Deficits similar for long-term type 1 diabetes and age-matched patients with type 2 diabetes
Administering a visual association test in patients with a small decline on the Mini-Mental State Examination during a 2-year period has substantial incremental value for identifying those at elevated risk for developing dementia.
Associations between cannabis use and cognitive functioning in adolescents and young adults are small.
Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying TherapyApril 26, 2018
The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.
Investigators believe the siponimod EXPAND study is the first trial of disease-modifying therapy to show superiority over a placebo for disability progression in SPMS.
The NIA-AA has proposed updates to the 2011 guidelines for symptomatic stages of Alzheimer's disease to include the idea that certain imaging and cerebrospinal fluid biomarkers are valid proxies for neuropathologic changes of AD.
A reasonable proportion of patients with epilepsy who have received treatment with pharmaceutical-grade cannabidiol products along with antiepileptic drugs have experienced a decrease in seizure frequency.
Cognitive decline risk is lowered in individuals aged 85 and older with high cholesterol.
An inverse relation was observed between epilepsy and cerebral palsy and 5-minute and 10-minute Apgar scores.
Modulate electrical stimulation of the amygdala may improve declarative memory without provoking any emotional reaction.
Among NFL football players who began their careers between 1982 and 1992, career participation in the NFL, compared with limited NFL exposure obtained primarily as an NFL replacement player during a league-wide strike, was not associated with a statistically significant difference in long-term all-cause mortality.
In patients with mild Alzheimer's disease solanezumab, an antibody designed to facilitate clearance of amyloid-beta plaques, did not significantly reduce cognitive decline over time.
Intake of primary nutrients and bioactives in green leafy vegetables is associated with slower cognitive decline.